Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases
详细信息 查看全文
- 作者：M.C. Sá ; dabaa ; I. Martí ; n-Estalb ; J.E. Puchea ; I. Castilla-Cortá ; zarb ; c ; iccortazar@itesm.mx" class="auth_mail" title="E-mail the corresponding author
- 关键词：ΔΨm ; membrane potential ; AD ; Alzheimer's disease ; AMPK ; adenosine&ndash ; monophosphate-activated kinase ; ATG proteins ; autophagy-related proteins ; ATP ; adenosine triphosphate ; CaMKs ; calcium-calmodulin-activated kinases ; CDKs ; cyclin-dependent kinases ; CNS ; central nervous system ; CREB ; cAMP response-element binding protein ; DJ-1 ; protein deglycase-1 ; eNOS ; endothelial nitric oxide synthase ; FADH2 ; flavin adenine nucleotide ; FMN ; flavin mononucleotide ; GH ; growth hormone ; GHR ; growth hormone rece
- 刊名：Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：1862
- 期：7
- 页码：1267-1278
- 全文大小：1049 K
文摘
- •
Mitochondrial dysfunction has been shown to compromise insulin signaling and oxidative capacity of mitochondrial electron transport chain.
- •
In neurodegenerative diseases, it has been found a mitochondrial dysfunction, leading to an increase in oxidative stress.
- •
The mere partial IGF-1 deficiency in animals is shown to produce mitochondrial dysfunction.
- •
The administration of low doses of IGF-1 has beneficial effects: restores physiological IGF-1 levels and improves insulin resistance.
- •
The administration of low doses of IGF-1 has hepatoprotective, neuroprotective and antioxidant effects and exherts mitocondrial protection.